Annals of oncology : official journal of the European Society for Medical Oncology
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
C Saura, J Cortés, S Modi, S-B Kim, E Hamilton, S A Hurvitz, I E Krop, G Curigliano, H Iwata, S-A Im, P Herbolsheimer, M Karnoub, A Boran, Y Kuwahara, A Egorov
Published: 202510.1016/j.annonc.2025.11.007
Abstract
BACKGROUND: Objective response rates in the DESTINY-Breast01/02/03 trials, which evaluated trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC), were 62%/70%/79%, respectively. PATI…
Preview only. Read the full abstract at the source